Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance
This study has been completed.
Information provided by (Responsible Party):
First received: December 23, 2009
Last updated: January 27, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2011|
|Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||March 1, 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, Hacquoil KE, Vasist Johnson LS, Barton ME, Dukes GE. The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. Crit Care. 2016 Aug 1;20(1):232. doi: 10.1186/s13054-016-1420-4.